A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability,Pharmacokinetics, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Phase of Trial: Phase I
Latest Information Update: 19 Sep 2018
At a glance
- Drugs MSB 0011359C (Primary)
- Indications Colorectal cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors EMD Serono
- 06 Sep 2018 Planned number of patients changed from 587 to 708.
- 06 Sep 2018 Planned End Date changed from 3 Oct 2019 to 1 Jul 2019.
- 05 Jun 2018 Results (n=80; as of 25 Oct 2017) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History